Chemotherapy Market Report 2025

The chemotherapy market size has grown rapidly in recent years. It will grow from $34 billion in 2024 to $37.78 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to cancer incidence increase, advancements in cancer diagnosis, innovation in drug development, clinical trial activity, access to healthcare, awareness campaigns.

The chemotherapy market size is expected to see rapid growth in the next few years. It will grow to $62.22 billion in 2029 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to immunotherapy integration, biosimilar adoption, emerging markets growth, genomic profiling, supportive care advances, regulatory facilitation. Major trends in the forecast period include digital health solutions, personalized medicine, continued oncology research, integration of artificial intelligence (ai), advancements in nanotechnology, home-based chemotherapy administration.

The anticipated rise in cancer prevalence is poised to drive growth in the chemotherapy market. Cancer, characterized by uncontrolled cell growth and dissemination, necessitates the use of potent chemicals, either in combination or individually, to eliminate rapidly proliferating cancer cells. The escalating incidence of cancer is expected to amplify the demand for chemotherapy. For instance, projections from the American Cancer Society Inc. indicate an expected 1.9 million new cancer cases in the US in 2023, marking an increase from 1.8 million cases diagnosed in 2020. The corresponding forecast for cancer-related deaths in 2023 is 609,820, compared to 606,520 in 2020. Consequently, the rising prevalence of cancer is a driving force in the chemotherapy market.

The anticipated rise in healthcare spending is expected to boost the growth of the chemotherapy market in the future. Healthcare spending encompasses the total expenditure on healthcare goods and services, including medical supplies, personal healthcare, long-term care, and public health services. It plays a crucial role in healthcare systems by providing the necessary resources for delivering healthcare services. An increase in healthcare spending fosters the growth of chemotherapy-related solutions and services, enhancing access to medical facilities and advanced treatments. For instance, in October 2023, the Peterson-KFF Health System Tracker, a US-based platform that monitors the U.S. health system's performance, reported that health spending is projected to grow slightly faster than the economy in 2025, reaching approximately 17.9% of GDP. This trend is expected to persist, with health spending growth likely to exceed overall economic growth, ultimately reaching 19.7% of GDP by 2032. Consequently, the rise in healthcare spending is a driving force behind the expansion of the chemotherapy market.

Leading players in the chemotherapy market are strategically concentrating on the introduction of innovative solutions, such as chemotherapy infusion pumps, to establish a competitive advantage. Chemotherapy infusion pumps are devices designed to deliver chemotherapy drugs directly into the bloodstream through an IV line. These pumps enable controlled administration, ensuring a gradual and steady infusion of drugs into the body. A case in point is Shanghai MicroPort Lifesciences Co. Ltd., a China-based medical technology developer and manufacturer, which unveiled AutoEx, its independently developed chemotherapy infusion pump, in March 2022. In clinical applications, specialized infusion pumps are frequently employed for precise and continuous infusion to maintain optimal blood medication concentration during chemotherapy, enhancing anti-cancer cell activity while mitigating side effects. AutoEx, designed for intravenous medication administration, serves the purpose of flushing or sealing PICCs, CVCs, and ports during chemotherapy, offering both intermittent and continuous usage options.

Major players in the chemotherapy market are actively pursuing strategic partnerships as a key avenue to facilitate the commercialization of cutting-edge medical devices aimed at enhancing chemotherapy services. These collaborative ventures are designed to capitalize on the unique strengths and resources of each partner, expediting advancements in cancer treatment, elevating patient outcomes, and addressing unmet medical needs. A notable example occurred in March 2023 when EVERSANA, a US-based provider of global services to the life sciences industry, joined forces with ChemoMouthpiece LLC, a US-based medical device company. This collaboration was forged to support the launch and commercialization of the Chemo Mouthpiece, an innovative intraoral ice pack delivering cryotherapy to the oral cavity of chemotherapy patients. The device plays a crucial role in preventing and treating oral mucositis, a prevalent and painful side effect of chemotherapy.

In February 2024, AbbVie, a global biopharmaceutical company based in the US, completed its acquisition of ImmunoGen for $10.1 billion. This acquisition is anticipated to strengthen AbbVie's oncology portfolio by incorporating ImmunoGen's cutting-edge antibody-drug conjugate technology. With this strategic initiative, AbbVie seeks to enhance its ability to develop advanced treatments for patients fighting different types of cancer. ImmunoGen is also a US-based company focused on the development of chemotherapy drugs.

Major companies operating in the chemotherapy market include GlaxoSmithKline plc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Merck & Co Inc., Sanofi SA, Celgene Corporation, Bristol-Myers Squibb Company, Amgen Inc., Bayer AG, Almatic Pharma LLC, AstraZeneca Pharmaceuticals, Astellas Pharma Inc., Puma Biotechnology Inc., Clovis Oncology Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson Services Inc., Mylan NV, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Gilead Sciences Inc., Biogen Inc., Eisai Co. Ltd., Ipsen SA, Spectrum Pharmaceuticals Inc., Seattle Genetics Inc., Exelixis Inc., Karyopharm Therapeutics Inc., Incyte Corporation, Agios Pharmaceuticals Inc., Epizyme Inc., Blueprint Medicines Corporation, Array BioPharma Inc., BeiGene Ltd., Halozyme Therapeutics Inc., MacroGenics Inc., Immunomedics Inc., TG Therapeutics Inc., Verastem Inc.

North America was the largest region in the chemotherapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the chemotherapy market report during the forecast period. The regions covered in the chemotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chemotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Chemotherapy is a treatment method that employs powerful drugs or medications to target and eliminate fast-growing cells in the body. These drugs are instrumental in killing cancer cells, which proliferate at an accelerated rate. Chemotherapy can involve using drugs individually or in combination to effectively treat various types of cancer.

The primary product types associated with chemotherapy include pumps, cannulas, catheters, and other related equipment. Chemotherapy infusion pumps are devices attached to the patient, delivering controlled doses of drugs gradually into the bloodstream. Services related to chemotherapy encompass treatments for specific types of cancer, such as blood cancer, throat cancer, lung cancer, ovarian cancer, stomach cancer, among others. These treatments typically involve a range of drugs including alkylating agents, antimetabolites, anti-tumor antibiotics, topoisomerase inhibitors, mitotic inhibitors, and other medications administered through oral and intravenous routes. Chemotherapy services are primarily utilized by hospitals, research institutes, and other related healthcare facilities.

The chemotherapy market research report is one of a series of new reports that provides chemotherapy optical components market statistics, including chemotherapy optical components industry global market size, regional shares, competitors with a chemotherapy optical components market share, detailed chemotherapy optical components market segments, market trends and opportunities, and any further data you may need to thrive in the chemotherapy optical components industry. This chemotherapy optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chemotherapy market includes revenues earned by entities by providing corticosteroids and hormonal agents as chemotherapy drugs. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.